News and Trends 14 Jul 2022Agomab bags $114 million in thriving regenerative medicine sector The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This… July 14, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2021Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening… December 21, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2021The Billion-Euro European Biotech Companies in 2022 Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European… December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2021Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has… May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jan 2021The 21 European Biotech Companies To Watch in 2021 As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies… January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020Argenx Follows up Phase III Success with Giant €785M Global Offering The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global… May 29, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2020Argenx’s Rare Disease Treatment Strikes Gold in Phase III The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved… May 26, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2019Argenx Raises Whopping €502M in Global Offering The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M)… November 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 3 Apr 2019€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could… April 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2018Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2018Argenx Attracts Huge €250M Investment Following Positive Phase II Trial Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results… September 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through… December 14, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017Belgian Antibody Proves Effective to Treat Myasthenia Gravis A Phase II proof of concept study has shown that one of Argenx' antibodies is effective in treating the neuromuscular disease myasthenia gravis. … December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 23 Aug 2017Dutch Biotech could treat Dyslipidemia with Belgian Nanobody Argenx' partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach… August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma argenx's 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn't been disclosed by how much… June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2017UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares… May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 13 Feb 2017Infographic: What’s in Europe’s Immuno-oncology Pipeline? While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer.… February 13, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016How is European Immuno-Oncology fighting Blood Cancer? From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's edition of the American Society… December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2016World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a… February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2016When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is… February 3, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email